• 1
    Van Der Meijden APM, Sylvester R, Oosterlinck W et al. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur. Urol. 2005; 48: 36371.
  • 2
    Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study. J. Urol. 2000; 163: 11249.
  • 3
    Jakse G, Hall R, Bono A et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: Long-term results of EORTC GU Group Phase II Protocol 30861. Eur. Urol. 2001; 40: 14450.
  • 4
    Zaak D, Hungerhuber E, Schneede P et al. Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer 2002; 95: 12348.
  • 5
    Guy L, Savareux L, Molinie V, Botto H, Boiteux J-P, Lebret T. Should bladder biopsies be performed routinely after Bacillus Calmette-Guerin treatment for high-risk superficial transitional cell cancer of the bladder? Eur. Urol. 2006; 50: 51620.
  • 6
    Highshaw RA, Tanaka ST, Evans CP, DeVere White RW. Is bladder biopsy necessary at three or six months post BCG therapy? Semin. Urol. Oncol. 2003; 2079.
  • 7
    Matsumoto H, Wada T, Fukunaga K, Yoshihiro S, Matsuyama H, Naito K. Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer. Jpn. J. Clin. Oncol. 2004; 34: 12430.
  • 8
    Kurth KH, Schellhammer PF, Okajima E et al. Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. Int. J. Urol. 1995; 2: 822.
  • 9
    Sobin LH, Wittekind C. TNM Classification of Malignant Tumours. 6th edn. Hoboken, New Jersey, John Wiley & Sons, 1997.
  • 10
    Epstein JI, Amin MB, Reuter VR et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am. J. Surg. Pathol. 1998; 22: 143548.
  • 11
    Papanicolaou GN. Criteria of Malignancy. In: PapanicolaouGN (ed). Atlas of Exfoliative Cytology. Harvard University Press, Cambridge, MA, 1954; 1321.
  • 12
    Dalbagni G, Rechtschaffen T, Herr HW. Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to bacillus Calmette-Guerin therapy? J. Urol. 1999; 162: 7089.
  • 13
    Raab SS, Grzybicki DM, Vrbin CM, Geisinger KR. Urine cytology discrepancies: Frequency, causes, and outcomes. Am. J. Clin. Pathol. 2007; 127: 94653.
  • 14
    Parwani AV, Levi AW, Epstein JI, Ali SZ. Urinary bladder biopsy with denuded mucosa: Denuding Cystitis-Cytopathologic correlates. Diagn Cytopathol. 2004; 30: 297300.
  • 15
    Leong AS, Wannakrairot P, Jose J, Milios J. Bacillus Calmette-Guerin-treated superficial bladder cancer: Correlation of morphology with immunophenotyping. J. Pathol. 1990; 162: 3541.
  • 16
    Owens CL, Epstein JI. Significance of denuded urothelium in papillary urothelial lesions. Am. J. Surg. Pathol. 2007; 31: 298303.